CG Oncology (CGON) Earnings Date & Reports
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer... Show more
CGON is expected to report earnings to fall 15.49% to -60 cents per share on August 07
CG Oncology (CGON) 2025 Year End Earnings Recap: Beat EPS Estimates Amid Clinical Momentum
Key Takeaways
- CG Oncology reported Q4 2025 net loss of $41.3 million, or ($0.52) per share, better than consensus estimates of ($0.61) per share.
- Full year 2025 revenue rose to $4.0 million from $1.1 million in 2024, driven by commercial and development activities.
- R&D expenses increased to $116.6 million for the year, reflecting higher clinical trial costs for cretostimogene grenadenorepvec (creto), including CMC (chemistry, manufacturing, and controls) expenses.
- Cash position stood at $742.2 million as of December 31, 2025, bolstering runway into first half of 2029 after ATM (at-the-market) equity sales.
- Key milestones ahead: Phase 3 PIVOT-006 topline data and BLA (Biologics License Application) submission in 2026 for high-risk non-muscle invasive bladder cancer (NMIBC).
Earnings Context and Why It Matters
As a late-stage biopharma focused on bladder-sparing therapies, CG Oncology's (CGON) 2025 year-end results highlight its investment in cretostimogene grenadenorepvec, an oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). With no commercial products yet, revenue remains modest from collaborations, while escalating R&D underscores progress toward pivotal trials and regulatory filings. Investors watch these earnings closely amid biotech volatility, as cash burn, trial outcomes, and FDA pathways dictate valuation. Strong liquidity mitigates dilution risks, but execution on upcoming catalysts will shape sentiment in a competitive oncology landscape.
CG Oncology reported financial results for the fourth quarter and full year ended December 31, 2025, its standard fiscal year-end. Q4 revenue totaled $4.0 million, comprising $3.2 million in commercial and development revenue and $0.8 million from licenses. This aligned with or exceeded limited expectations, though consensus focused on EPS.
Net loss widened to $41.3 million, or ($0.52) per share, from $31.8 million, or ($0.46) per share, in Q4 2024, driven by higher operating expenses of $194.8 million for the quarter. R&D rose to $30.0 million (from $26.8 million), due to clinical trials and headcount growth; G&A (general and administrative) hit $18.0 million (from $11.7 million), reflecting personnel and marketing costs.
For full year 2025, revenue grew to $4.0 million from $1.1 million in 2024. Net loss expanded to $161.0 million, or ($2.08) per share, from $88.0 million, or ($1.41) per share. Annual R&D expenses climbed to $116.6 million (from $82.1 million), and G&A to $73.5 million (from $33.7 million). The EPS beat analyst forecasts, with Q4 loss narrower than the ($0.61) consensus, boosting confidence despite increased spending.
Cash, cash equivalents, and marketable securities reached $742.2 million at year-end, up from $680.3 million at Q3-end via $98.4 million in ATM sales, and ~$903 million by late February 2026. No formal guidance issued, but updates emphasized clinical progress.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis.
Market Reaction and Investor Sentiment
CGON shares rose on February 27, 2026, closing at $58.80 after opening at $55.79, reflecting a positive response to the EPS beat and clinical updates. Volume surged to over 1 million shares. Sentiment remains optimistic, buoyed by trial advancements and cash strength, though biotech peers' volatility tempers gains. Analysts noted the narrower loss and milestones as supportive.
Forward Outlook and Key Factors to Monitor
Following 2025 results, CG Oncology's focus shifts to 2026 catalysts for cretostimogene in NMIBC (non-muscle invasive bladder cancer). Topline data from Phase 3 PIVOT-006 trial in intermediate-risk NMIBC is slated for the first half of 2026, expedited nearly a year ahead. This first randomized Phase 3 in the space targets broad patients per AUA/SUO guidelines.
Phase 2 CORE-008 Cohort CX first results, combining cretostimogene with gemcitabine in high-risk BCG (Bacillus Calmette-Guérin)-exposed/unresponsive NMIBC, also expected in H1 2026. Durability data from BOND-003 Cohort C/P and CORE-008 Cohort A will follow throughout the year.
A BLA submission for high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) ± Ta/T1 is planned for 2026, based on prior positive data like 95.7% high-grade event-free survival at 3 months in Cohort P. Cash of ~$903 million supports operations into H1 2029, funding these without near-term pressure.
Investors should track trial readouts for efficacy/safety, regulatory feedback, and expense trends amid headcount growth. Industry dynamics, including BCG shortages, could favor bladder-sparing alternatives if successful.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
Industry Biotechnology